Commentary: Phosducin-like 3 is a novel prognostic and onco-immunological biomarker in glioma: a multi-omics analysis with experimental verification
2024

Phosducin-like 3 as a Biomarker in Glioma

Commentary Evidence: moderate

Author Information

Author(s): Xue Jihao, Yin Qijia, Wang Ming, Li Yanling

Primary Institution: Southwest Medical University

Hypothesis

Is PDCL3 a potential prognostic biomarker for glioma?

Conclusion

The study highlights the need for rigorous validation of predictive models in glioma research.

Supporting Evidence

  • PDCL3 was identified as a potential prognostic biomarker for glioma.
  • The authors constructed a nomogram based on Cox regression analysis.
  • Statistical tests indicated that several variables did not meet the proportional hazards assumption.

Takeaway

This article talks about a study that found a new marker for glioma, but it also warns that researchers need to be careful when using certain statistical methods.

Methodology

The authors performed univariate and multivariate Cox regression analyses and tested the proportional hazards assumption.

Potential Biases

There is a risk of inaccuracies and biases if the proportional hazards assumption is violated.

Limitations

The study emphasizes the importance of adhering to the proportional hazards assumption in Cox regression models.

Statistical Information

P-Value

p > 0.05

Statistical Significance

p > 0.05

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1499286

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication